Related Experiment Videos
Verapamil for refractory ventricular fibrillation during cardiac operations in patients with cardiac hypertrophy
Insights
Calcium-entry blockers like verapamil may help treat ventricular fibrillation in patients with cardiac hypertrophy undergoing surgery. This approach proved effective when standard treatments failed, offering a new therapeutic option.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Calcium-entry blockers are known to prevent ventricular fibrillation during myocardial ischemia in animal models.
- Their potential role in limiting infarct size and preserving myocardium during cardiopulmonary bypass is recognized.
- Clinical applications for ventricular dysrhythmias linked to ischemia remain underexplored.
Observation:
- Four patients with significant cardiac hypertrophy experienced ventricular fibrillation post-cardiopulmonary bypass.
- These dysrhythmias were resistant to defibrillation and conventional pharmacologic treatments.
- Verapamil administration preceded successful defibrillation in all cases.
Findings:
- Verapamil effectively treated refractory ventricular fibrillation in patients with cardiac hypertrophy after cardiopulmonary bypass.
- Successful defibrillation was achieved post-verapamil administration in all reported cases.
- This suggests a potential therapeutic role for verapamil in specific perioperative cardiac scenarios.
Implications:
- Verapamil may serve as a crucial adjunct therapy for managing life-threatening ventricular dysrhythmias in complex cardiac surgical patients.
- Further clinical investigation is warranted to establish the efficacy and safety of calcium-entry blockers in this patient population.
- These findings could influence perioperative management strategies for patients with cardiac hypertrophy and risk of ventricular fibrillation.
Abstract:
Calcium-entry blockers prevent ventricular fibrillation during acute myocardial ischemia in laboratory animals. They may be useful as an adjunct to cold cardioplegia by preserving the myocardium during cardiopulmonary bypass. Their use may limit myocardial infarct size. However, the clinical application of calcium-entry blockers for ventricular dysrhythmias associated with myocardial ischemia has been little explored, as yet. We describe four patients, all of whom had significant cardiac hypertrophy (two had idiopathic hypertrophic subaortic stenosis; one had transposition of great vessels; and one had aortic stenosis) and in whom ventricular fibrillation developed after rewarming or shortly after the termination of bypass. The dysrhythmias were refractory to multiple attempts at defibrillation and conventional pharmacologic interventions. However, in each case, defibrillation was successful after administration of verapamil.